{"id":574157,"date":"2026-02-24T08:50:26","date_gmt":"2026-02-24T08:50:26","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/?p=574157"},"modified":"2026-02-24T08:51:28","modified_gmt":"2026-02-24T08:51:28","slug":"navigating-fda-complete-response-letters-clarivate","status":"publish","type":"post","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/blog\/navigating-fda-complete-response-letters-clarivate\/","title":{"rendered":"Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval"},"content":{"rendered":"

When a drug\u2019s path to market is complicated by an unanticipated regulatory action, pharmaceutical companies face a critical juncture: respond effectively and quickly, or watch development timelines\u2014and competitive advantage\u2014slip away. Two of the therapies highlighted in the Clarivate \u201cDrugs to Watch 2026\u201d report<\/a>, Sanofi\u2019s\u202ftolebrutinib\u202fand\u202fCorcept\u202fTherapeutics\u2019\u202frelacorilant, faced such\u202fsetbacks in the last days of 2025.\u202fThe FDA sent Complete Response Letters (CRLs) for\u202ftolebrutinib<\/a>\u202fto treat non-relapsing secondary progressive multiple sclerosis (nrSP-MS)\u202fon December 23, 2025,\u202fand\u202frelacorilant<\/a>\u202fto treat Cushing syndrome\u202fon\u202fDecember 30, 2025.<\/p>\n

The decisions\u202fsurprised\u202fmany observers.\u202fTolebrutinib\u202fheld both Priority Review and Breakthrough Therapy designations,\u202fwhile\u202frelacorilant\u2019s\u202fpivotal GRACE trial\u202fhad\u202fmet its primary endpoint\u202fwith supportive confirmatory\u202fdata from the GRADIENT trial.\u200b<\/p>\n

 <\/p>\n

What is a complete response letter (CRL)? <\/strong><\/h3>\n

Created in 2008 to replace the FDA’s “approvable” and “not approvable” letters, CRLs were designed as a neutral mechanism to communicate that an application cannot be approved as submitted. Despite their official neutrality, CRLs carry significant weight,\u202fdetail specific deficiencies identified by the FDA,\u202fand typically recommend\u202fsteps to\u202faddress them. Common reasons include safety or efficacy concerns requiring\u202fadditional\u202fdata, manufacturing or quality control deficiencies, inadequate risk management\u202fstrategies\u202fand insufficient evidence for benefit-risk assessment.\u200b<\/p>\n

CRLs are setbacks, not rejections<\/strong><\/p>\n

Although setbacks,\u202fCRLs are not rejections:\u202froughly 41% of submissions<\/a>\u202freceive a CRL, and more than half of those\u202fultimately gain\u202fapproval.\u202fUnderstanding what\u202fdrove these decisions and what comes next offers important lessons for developers navigating regulatory expectations.<\/p>\n

For Sanofi and Corcept Therapeutics, the path forward requires sophisticated intelligence, precedent analysis and strategic evidence generation. Clarivate\u2019s integrated, artificial intelligence (AI)-enabled solutions are designed to support regulatory decision-making, strengthen resubmission strategies and help advance therapies to patients.<\/p>\n

 <\/p>\n

Distinct regulatory challenges require tailored strategies <\/strong><\/h3>\n

Before examining specific solutions, it’s important to recognize that Sanofi and Corcept face fundamentally different CRL challenges requiring tailored approaches.<\/p>\n

Sanofi’s tolebrutinib\u202fconfronts a safety-focused CRL centered on severe drug-induced liver injury (DILI) risk that the FDA characterized as \u201csubstantial and unusually high.\u201d The agency concluded it \u201cwas unable to identify a population for which the benefit could be clearly established and for which that benefit would be anticipated to outweigh the serious risk of severe DILI.\u201d This requires Sanofi to either demonstrate enhanced risk mitigation strategies, identify lower-risk patient subpopulations or generate additional safety evidence.\u200b<\/p>\n

Corcept’s relacorilant\u202freceived an evidence adequacy CRL in which the FDA acknowledged the GRACE trial met its primary endpoint but stated it “could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.” This suggests the agency needs more comprehensive demonstration of clinical meaningfulness and benefit-risk across the heterogeneous Cushing’s syndrome population.\u200b<\/p>\n

 <\/p>\n

How the Clarivate integrated intelligence platform supports CRL responses <\/strong><\/h3>\n

Clarivate integrated data platforms and AI-powered solutions provide life sciences companies with intelligence, analytical capabilities and strategic insights. Our AI-powered approach can dramatically reduce the time from question to insight throughout the drug development and commercialization lifecycle, transforming processes that previously required weeks of manual analysis into insights delivered in hours.<\/p>\n

This integrated approach proved particularly valuable when choosing our Drugs to Watch and, for life sciences companies, its value applies to responding to CRLs, where multiple data sources and analytical perspectives must converge rapidly.\u200b Real-time updates of critical information from trusted sources support agile responses, whether re-evaluating the impact of regulatory decisions on the potential market, understanding the impact of a drug on patients or determining the path forward after a CRL.<\/p>\n

 <\/p>\n

Clarivate solutions that enable stronger CRL resubmissions <\/strong><\/h3>\n

Clarivate offers\u202f10 integrated, AI-enhanced datasets spanning the R&D and commercialization lifecycle, with several proving especially critical for CRL response:\u200b<\/p>\n

 <\/p>\n

    \n
  1. Cortellis Regulatory Intelligence<\/a> (with AI-powered Regulatory Assistant): e.g., precedent analysis, regulatory strategy development, understanding FDA’s evidence bar<\/li>\n
  2. Cortellis Clinical Trials Intelligence<\/a>: e.g., design enhanced safety monitoring protocols and potential subpopulation trials with the highest success probability<\/li>\n
  3. DRG Fusion<\/a> (real-world data analytics platform): e.g., generate additional effectiveness and safety evidence from real-world sources, identify lower-risk subpopulations<\/li>\n
  4. Epidemiology Intelligence<\/a>: e.g., quantify addressable patient populations in lower-risk subgroups, define subpopulations with clearest demonstrated benefit<\/li>\n
  5. Cortellis Competitive Intelligence<\/a>: e.g., maintain strategic awareness during extended development and use predictive analytics in pharma to understand the impact of decisions on the launch timeline and sales forecasts<\/li>\n
  6. Disease Landscape & Forecast<\/a>: e.g., maintain competitive awareness and portfolio strategy during extended development<\/li>\n
  7. Access and reimbursement intelligence<\/a>: e.g., build and refine market access strategy during extended development to accelerate post-approval uptake<\/li>\n<\/ol>\n

    The next post in this series examines how these AI-powered Clarivate tools can help companies navigate risk-benefit evaluations in regulatory submissions<\/a>.<\/p>\n

    Learn more about our 2026 Drugs to Watch <\/a>, and you can read about how Clarivate is using AI tools<\/a> to empower its clients to make better decisions faster.
    \n<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

    When a drug\u2019s path to market is complicated by an unanticipated regulatory action, pharmaceutical companies face a critical juncture: respond effectively and quickly, or watch development timelines\u2014and competitive advantage\u2014slip away….<\/p>\n","protected":false},"author":141,"featured_media":574158,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_links_to":"","_links_to_type":0,"footnotes":""},"categories":[19],"tags":[40,414,34,2501,76,90,333,381,30,2737,2625],"class_list":["post-574157","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","tag-biopharma","tag-biotech","tag-clinical-trials","tag-commercialization","tag-fda","tag-market-access","tag-pharma","tag-real-world-data","tag-regulatory","tag-safety","tag-u-s"],"acf":[],"lang":"en","translations":{"en":574157,"ja":574218},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/574157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/users\/141"}],"replies":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/comments?post=574157"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/574157\/revisions"}],"predecessor-version":[{"id":574373,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/574157\/revisions\/574373"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media\/574158"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=574157"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/categories?post=574157"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/tags?post=574157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}